Ripei Biosciences' PrimCell® Device Approved for Market Release, Revolutionizing Skin Repair

Ripei Biosciences, a company based in Suzhou, has achieved a significant milestone with the approval of its PrimCell® self-cell collection device for market release. This innovative artificial skin treatment system is designed for the management of skin damage repair and is applicable to various types of wounds, including burn wounds, vitiligo, superficial scars, and chronic wounds. The approval marks a notable advancement in the field of regenerative medicine, offering a new solution for patients suffering from skin injuries and related conditions.

The PrimCell® system represents a breakthrough in skin repair technology. It provides a non-invasive method for collecting and utilizing a patient's own cells to promote healing. This approach not only accelerates the recovery process but also minimizes the risk of rejection and infection, as the cells used are derived from the patient's own body. The device's ability to manage a wide range of skin conditions makes it a versatile tool for healthcare professionals, enhancing their capacity to provide comprehensive care to patients.

Ripei Biosciences, established in 2021, specializes in skin regeneration technology and related clinical products. The company's focus on developing innovative solutions for skin repair has led to the creation of the PrimCell® device, which fills a technological gap in the domestic market for immediate skin cell separation and repair. The device uses a proprietary two-step method to quickly separate and obtain skin cells from healthy skin tissue, which can then be applied directly to the wound without the need for cultivation. This process leverages the patient's own wound as an incubator to complete skin regeneration and repair.

In addition to the PrimCell® device, Ripei Biosciences has developed a real-time cell detection and analysis system. This system, a fully automated high-throughput counting machine, works in conjunction with the PrimCell® device to collect and analyze data on the concentration, viability, diameter, and clustering rate of the obtained epidermal cells. This information provides a basis for implementing treatment plans and ensures the effectiveness of the PrimCell® technology by stably obtaining skin cells with a viability of over 90%.

To better meet clinical needs and promote the application of regenerative medicine, Ripei Biosciences is collaborating with leading medical institutions. These partnerships aim to integrate resources and accelerate the conversion of regenerative medicine research into practical applications, providing patients with more advanced and effective treatment options. The company's efforts are part of a broader trend in Suzhou, where the biotechnology and new medical device industry cluster has seen rapid development. The region is home to nearly 590 enterprises in this sector, with a total industrial output value exceeding 500 billion yuan.

The approval of the PrimCell® device underscores the growing importance of regenerative medicine in modern healthcare. As the population ages and the prevalence of chronic diseases increases, there is a growing demand for innovative treatments that can address complex medical conditions. The PrimCell® system addresses this need by providing a cutting-edge solution for skin repair, which can significantly improve the quality of life for patients. The market release of the PrimCell® self-cell collection device is expected to have a profound impact on the healthcare industry, offering a more efficient and effective treatment option for patients with skin damage and reducing the need for traditional surgical interventions.